Mylan, Fujifilm score EU thumbs-up for Humira biosimilar, putting more pressure on AbbVie
admin 20th September 2018 Uncategorised 0AbbVie and its investors have been fretting over the potential impact of biosimilar competition to Humira—the world’s top-selling drug, with more than $18 billion a year in sales—and now they have another contender to worry about. Mylan and Fujifilm’s Hulio is the fifth Humira biosimilar to win marketing approval in Europe.
More: Mylan, Fujifilm score EU thumbs-up for Humira biosimilar, putting more pressure on AbbVie
Source: fierce